Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT05175664 Active, not recruiting - Alzheimer Disease Clinical Trials

Novel Diagnostic and Disease Stage Biomarkers in AD

TRACK-AD
Start date: January 1, 2022
Phase:
Study type: Observational

This study will investigate the efficacy of novel biomarkers, namely blood-based biomarkers, pupillometry and actigraphy to track and predict progression of Alzheimer's disease (AD). Furthermore, the study will investigate the diagnostic value of pupillometry and actigraphy for AD.

NCT ID: NCT05173922 Active, not recruiting - Alzheimer Disease Clinical Trials

"Safety in Dementia": An Online Caregiver Intervention

Start date: May 22, 2022
Phase: N/A
Study type: Interventional

In an online randomized trial of Safety in Dementia with national recruitment and longitudinal follow-up, we will recruit informal caregivers of community-dwelling adults with dementia who have firearm access.

NCT ID: NCT05145881 Active, not recruiting - Alzheimer Disease Clinical Trials

Effect of Probiotics in Alzheimer's Disease

Start date: April 2, 2020
Phase: N/A
Study type: Interventional

In this clinical trial, five strains of probiotics (Bifidobacterium breve Bv-889, B. longum subspecies infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) with anti-oxidant and anti-inflammatory functions will been applied to slow down the development of the Alzheimer's disease through regulating the intestinal flora and immune system of patients with mild to moderate Alzheimer's disease symptoms. The efficacy of probiotic treatment against Alzheimer's disease will be evaluated.

NCT ID: NCT05063539 Active, not recruiting - Alzheimer Disease Clinical Trials

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Start date: September 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

NCT ID: NCT05060848 Active, not recruiting - Alzheimer Disease Clinical Trials

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

Start date: April 1, 2021
Phase:
Study type: Observational

Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. We will compare blood levels of hydrogen sulfide across groups of people with and without dementia. We will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. Our goal is to identify a biomarker of vascular dysfunction in dementia.

NCT ID: NCT05058040 Active, not recruiting - Alzheimer Disease Clinical Trials

A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

Start date: June 2, 2021
Phase: Phase 4
Study type: Interventional

A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)

NCT ID: NCT05027789 Active, not recruiting - Clinical trials for Cognitive Impairment

Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention

BB2
Start date: August 13, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to determine if training in memory support aids and healthy lifestyle activities (physical exercise, mentally stimulating activities and stress management) can have a positive effect on memory, thinking, and activities that people do every day. Participation in this study will involve being placed into one of two groups: a Self-Guided Intervention Group or a Structured Intervention Group. Both groups will be asked to attend group sessions in which they will be provided education on memory support strategies and lifestyle changes. The Structured Intervention Group will also be provided with an iPad and a digital application (called EMMA) to track their activity. Study participation involves a 6-month intervention and completing outcome measures at 4 different time points for up to a year.

NCT ID: NCT05026177 Active, not recruiting - Alzheimer Disease Clinical Trials

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

REFOCUS-ALZ
Start date: November 18, 2021
Phase: Phase 3
Study type: Interventional

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.

NCT ID: NCT05015374 Active, not recruiting - Clinical trials for To Evaluate the Possible Benefit of Astaxanthin on Alzheimer Disease

Effect of Astaxanthin on the Patients With Alzheimer Disease

Start date: November 14, 2018
Phase: N/A
Study type: Interventional

This study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of Astaxanthin on Alzheimer disease. The enrolled Alzheimer patients will take Astaxanthin or placebo for 1 year. We will follow up Mini-Mental State Examination, Cognitive Ability Screening Instrument, Clinical Dementia Rating, and Neuropsychiatric Inventory at the end of the study.

NCT ID: NCT05012410 Active, not recruiting - Alzheimer Disease Clinical Trials

WeCareAdvisor Study for Caregivers of People Living With Dementia

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

The WeCareAdvisor is an online tool to help caregivers manage behavioral and psychological symptoms of people living with dementia. The trial will evaluate its efficacy to reduce caregiver distress, improve confidence managing behaviors, as well as reduce occurrences and severity of behavioral and psychological symptoms. Visit https://wecareadvisorstudy.com/ for more information.